4

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
INRP:032--1/HYL	08/675,887
Applicant	
Ruth A. Gjerset	
Filing Date:	Group:
July 5, 1996	1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
bb	A1	5,527,676	06/18/96	Vogelstein *et al.*			
bb	A2	5,532,220	07/02/96	Lee *et al.*			

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 039323	10/03/90	Europe			
bb	B2	WO 90/05180	05/17/90	PCT			
bb	B3	WO 91/15580	10/17/91	PCT			
bb	B4	WO 94/18992	09/01/94	PCT			
bb	B5	WO 94/24297	10/27/94	PCT			
bb	B6	WO 95/14101	05/26/95	PCT			
bb	B7	WO 95/14102	05/26/95	PCT			
bb	B8	WO 95/23867	09/08/95	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Adler *et al.*, "UV Irradiation and Heat Shock Mediate JNK Activation via Alternate Pathways," *Journal of Biological Chemistry*, 270(44): 26071-26077, 1995.

Examiner: Brenda Brumback | **Date Considered:** 10-16-2001

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant's	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C2	Ali-Osman *et al.*, "Enhanced repair of a Cisplatin-Damaged Reporter Chloramphenicol-O-Acetyltransferase Gene and Altered Activities of DNA Polymerases $\alpha$and β, and DNA Ligase in Cells of a Human Malignant Glioma Following In Vivo Cisplatin Therapy," *Journal of Cellular Biochemistry*, 54: 11-19, 1994.
	C3	Baker *et al.*, 'Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas," *Science*, 244:217-221, April 1989.
	C4	Baker *et al.*, "p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis," *Cancer Research*, 50:7717-7722, December 1990.
	C5	Baker *et al.*, "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53," *Science*, 249: 912-915, 1990.
	C6	Baverstock and Will, "Evidence for the dominance of direct excitation of DNA in the formation of strand breaks in cells following irradiation," *International Journal of Radiation Biology*, 55(4): 563-568, 1989.
	C7	Bigner *et al.*, "Cytogenetics of Human Brain Tumors," *Cancer Genetic Cytogenetics*, 47: 141-154, 1990.
	C8	Bigner *et al.*, "Heterogeneity of Genotypic and Phenotypic Characteristics of Fifteen Permanent Cell Lines Derived from Human Gliomas," *Journal of Neuropathology and Experimental Neurology*, 40(3): 201-229, 1981.
	C9	Carter *et al.*, "Adenovirus Containing a Deletion of the Early Region 2A Gene Allows Growth of Adeno-Associated Virus with Decreased Efficiency," *Virology*, 191:473-476, 1992.
	C10	Clarke *et al.*, "Thymocyte apoptosis induced by p53-dependent and independent pathways," *Nature*, 362: 849-852, 193
	C11	Davidson *et al.*, "A Model System for *In Vivo* Gene Transfer into the Central Nervous System Using an Adenoviral Vector," *Nature Genetics*, 3:219-223, March 1993.
	C12	DiLeonardo *et al.*, "DNA damage triggers a prolonged p53-dependent G_1 arrest and long-term induction of Cip1 in normal human fibroblasts," *Genes and Development*, 8: 2540-2551, 1994.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant's	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C13	Diller *et al.*, "p53 Functions as a Cell Cycle Control Protein in Osteosarcomas," *Molecular and Cellular Biology*, 10(11):5772-5781, November 1990.
	C14	Donehower *et al.*, "Deficiency of p53 accelerates mammary tumorigenesis in *Wnt-1* transgenic mice and promotes chromosomal instability," *Genes and Development*, 9: 882-895, 1995.
	C15	El-Deiry *et al.*, "WAF1/CIP1 Is Induced in p53-mediated G_1 Arrest and Apoptosis," *Cancer Research*, 54: 1169-1174, 1994.
	C16	El-Diery *et al.*, "WAF1, a Potential Mediator of p53 Tumor Suppression," *Cell*, 75: 817-825, 1993.
	C17	Eliyahu *et al.*, "Meth A Fibrosarcoma Cells Express Two Transforming Mutant p53 Species," *Oncogene*, 3:313-321, 1988.
	C18	Eliyahu *et al.*, "p53 - A Potential Suppressor Gene?" *Journal of Cellular Biochemistry*, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C:264, Abstract No. I 030, February 3 - March 11, 1990.
	C19	Eliyahu *et al.*, "Wild-Type p53 Can Inhibit Oncogene-Mediated Focus Formation," *Proc. Natl. Acad. Sci. USA*, 86:8763-8767, November 1989.
	C20	Evans *et al.*, "Differential Sensitivity to the Induction of Apoptosis by Cisplatin in Proliferating and Quiescent Immature Rat Thymocytes Is Independent of the Levels of Drug Accumulation and DNA Adduct Formation," *Cancer Research*, 54: 1596-1603, 1994.
	C21	Fanjul *et al.*, "A new class of retinoids with selective inhibition of AP-1 inhibits proliferation," *Nature*, 372: 107-111, 1994.
	C22	Finlay *et al.*, "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," *Cell*, 57:1083-1093, June 1989.
	C23	Fraval *et al.*, "Increased Sensitivity of UV-Repair-Deficient Human Cells to DNA Bound Platinum Products Which Unlike Thymine Dimers Are Not Recognized by an Endomuclease Extracted From *Micrococcus Luteus*," *Mutation Research*, 51: 121-132, 1978.
	C24	Fujiwara *et al.*, "Induction of Chemosensitivity in Human Lung Cancer Cells In Vivo by Adenovirus-mediated Transfer of the Wild-Type p53 Gene," *Cancer Research*, 54: 2287-2291, 1994.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Gebhardt *et al.*, "A Tumor Suppressor Proto-Oncogene p53 Can Block Progression Through the Cell Cycle," Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research, Subspecialty Meetings, Sheraton Washington Hotel, Washington, D.C., May 6, 1990, Abstract.
	C26	Gipp *et al.*, "DNA-Damage Induced in HT-29 Colon Cancer Cells by Exposure to 1-Methyl-2-Nitrosoimidazole, A Reductive Metabolite of 1-Methyl-2-Nitroimidazole," *Biochemical Pharmacology*, 42 (Suppl): S127-S133, 1991.
	C27	Gjerset *et al.*, "Use of Wild-Type p53 to Achieve Complete Treatment Sensitization of Tumor Cells Expressing Endogenous Mutant p53," *Molecular Carcinogenesis*, 14:275-285, 1995.
	C28	Graham and Prevec, "Manipulation of Adenovirus Vectors," *Methods in Molecular Biology, Gene Transfer and Expression Protocols*, E.J. Murray (ed.), The Humana Press, Inc., Vol. 7, Chapter 11, pp. 109-128, 1991.
	C29	Hinds *et al.*, "Mutation is Required to Activate the p53 Gene for Cooperation with the *ras* Oncogene and Transformation," *Journal of Virology*, 63(2):739-746, February 1989.
	C30	Hinds *et al.*, "The p53 Proto-Oncogene Can Suppress Transformation by Other Oncogenes, and Mutations in the Proto-Oncogene Can Activate the Gene for Transformation," *Common Mechanisms of Transformation by Small DNA Tumor Viruses*, Chapter 7, pp. 83-101, 1989.
	C31	Hinds, "Biological Consequences of Mutation of the p53 Proto-Oncogene," *UMI Dissertation Services*, October 1989.
	C32	Huang *et al.*, "Suppression of the Neoplastic Phenotype by Replacement of the RB Gene in Human Cancer Cells," *Science*, 242-1563-1566, December 1988.
	C33	Izumoto *et al.*, "Homozygous deletions of $p16^{INK4A}$/MTS1 and $p15^{INK4B}$/MTS2 genes in glioma cells and primary glioma tissues," *Cancer Letters*, 97: 241-247, 1995.
	C34	Jen *et al.*, "Deletion of p16 and p15 Genes in Brain Tumors," *Cancer Research*, 54: 6353-6358, 1994.
	C35	Kaden *et al.*, "High frequency of large spontaneous deletions of DNA in tumor-derived CHEF cells." *Proceedings of the National Academy of Science USA*, 86: 2306-2310, 1989.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant's	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C36	Kamb, Alexander, "Cell-Cycle Regulators and Cancer," *Trends In Genetics*, 11(4): 136-140, 1995.
	C37	Kashani-Sabet *et al.*, "Cyclosporin A Suppresses Ciplatin-induced c-*fos* Gene Expression in Ovarian Carcinoma Cells," *Journal of Biological Chemistry*, 265(19): 11285-11288, 1990.
	C38	Kashani-Sabet *et al.*, "Differential Oncogene Amplification in Tumor Cells from a Patient Treated with Cisplatin and 5-Fluorouracil," *European Journal of Cancer*, 26(3): 383-390, 1990.
	C39	Kimler, "The 9L Rat Brain Tumor Model for Pre-Clinical Investigation of Radiation-chemotherapy Interactions," *Journal of Neuro-Oncology*, 20:103-109, 1994.
	C40	Klessig *et al.*, "Introduction, Stable Integration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product is Toxic to the Recipient Human Cell," *Molecular and Cellular Biology*, 4(7):1354-1362, July 1984.
	C41	Lamb and Crawford, "Characterization of the Human p53 Gene," *Molecular and Cellular Biology*, 6(5):1379-1385, May 1986.
	C42	Lane, D.P. "p53, guardian of the genome," *Nature*, 358: 15-16, 1992.
	C43	Lee *et al.*, "Molecular Basis of Tumor Suppression by the Human Retinoblastoma Gene," *Journal of Cellular Biochemistry*, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C, Abstract No. I 001, February 3 - March 11, 1990.
	C44	Levine *et al.*, "The p53 Growth Suppressing Gene Can Inhibit Transformation by Other Oncogenes," *The Journal of Cell Biology*, The American Society for Cell Biology, Twenty-ninth Annual Meeting, November 5-9, 1989, Houston, Texas, Abstracts, 1989.
	C45	Levine *et al.*, "The p53 Growth Suppressor Gene," *Journal of Cellular Biochemistry*, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C:264, Abstract No. I 029, February 3 - March 11, 1990.
	C46	Liu and Miller, "Eukaryotic DNA Topoisomerases: Two Forms of Type I DNA Topoisomerases from HeLa Cell Nuclei," *Proc Natl Acad Sci USA*, 48(6):3487-3491, June 1981.
	C47	Liu *et al.*, "Cleavage of DNA by Mammalian DNA Topoisomerase II," *Journal of Biological Chemistry*, 258(24): 15365-15370, 1983.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C48	Lotem and Sachs, "Hematopoietic Cells From Mice Deficient in Wild-Type p53 Are More Resistant to Induction of Apoptosis by Some Agents," *Blood*, 82(4): 1092-1096, 1993.
	C49	Lowe *et al.*, "p53 Status and the Efficacy of Cancer Therapy In Vivo," *Science*, 266: 807-810, 1994.
	C50	Lowe *et al.*, "p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents," *Cell*, 74: 957-967, 1993.
	C51	Lukas *et al.*, "Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16," *Nature*, 375: 503-506, 1995.
	C52	Malkin *et al.*, "Mutant p53 Confers Tumorignicity to a Cell Line Lacking p53: Evidence for a Second p53 Function in Tumor Formation," *Blood*, 76(10, Supp. 1):238a, 1990.
	C53	Mercer *et al.*, "Antiproliferative Effects of Wild Type Human P53," *Journal of Cellular Biochemistry*, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C:264, Abstract No. I 224, February 3 - March 11, 1990.
	C54	Mercer *et al.*, "Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53," *Proceedings of the National Academy of Science USA*, 87: 6166-6170, 1990.
	C55	Minna *et al.*, "The Molecular Pathogenesis of Lung Cancer Involves the Accumulation of a Large Number of Mutations in Dominant Oncogenes and Multiple Tumor Suppressor Genes (Recessive Oncogenes)," *Journal of Cellular Biochemistry*, UCLA Symposia on Molecular & Cellular Biology, Abstracts, 19th Annual Meeting, Supplement 14C:264, Abstract No. I 003, February 3 - March 11, 1990.
	C56	Miyashita *et al.*, "Tumor suppressor p53 is a regulator of *bcl-2* and *bax* gene expression in vitro and in vivo," *Oncogene* 9: 1799-1805, 1994.
	C57	Moulton *et al.*, "MTS1/p16/CDKN2 Lesions in Primary Glioblastoma Multiforme," *American Journal of Pathology*, 146(3): 613-619, 1995.
	C58	Moynihan *et al.*, "The Role of Chemotherapy in the Treatment of Primary Tumors of the Central Nervous System," *Cancer Investigation*, 12(1): 88-97, 1994.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant	Applicant	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Ruth A. Gjerset	
	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C59	Nigro *et al.*, "Mutations in the p53 gene occur in diverse human tumour types," *Nature*, 342: 705-708, 1989.
	C60	Nishikawa *et al.*, "Loss of $P16^{INK4}$ Expression is Frequent in High Grade Gliomas," *Cancer Research*, 55: 1941-1945, 1995.
	C61	Noble *et al.*, "Effects of Exogenous Wild-Type p53 on a Human Lung Carcinoma Cell Line with Endogenous Wild-Type p53," *Experimental cell Research*, 203: 297-304, 1992.
	C62	Oshita and Saijo, "Rapid Polymerase Chain Reaction Assay to Detect Variation in the Extent of Gene-Specific Damage Between Cisplatin- or VP-16-Resistant and Sensitive Lung Cancer Cell Lines," *Jpn. J. Cancer Res.*, 85:669-673, July 1994.
	C63	Rogel *et al.*, "p53 Cellular Tumor Antigen: Analysis of mRNA Levels in Normal Adult Tissues, Embryos, and Tumors," *Molecular and Cellular Biology*, 5(10): 2851-2855, 1985.
	C64	Sager, "Tumor Suppressor Genes: The Puzzle and the Promise," *Science*, 246:1406-1412, December 1989.
	C65	Scanlon *et al.*, "Overexpression of DNA Replication and Repair Enzymes in Cisplatin-Resistant Human Colon Carcinoma HCT8 Cells and Circumvention by Azidothymidine," *Cancer Communications*, 1(4):269-275, 1989.
	C66	Scanlon *et al.*, "Cisplatin Resistance in Human Cancers," *Pharmaceutical Therapy*, 52: 385-406, 1991.
	C67	Scanlon *et al.*, "Molecular Basis of Cisplatin Resistance in Human Carcinomas: Model Systems and Patients," *Anticancer Research*, 9:1301-1312, 1989.
	C68	Shaw *et al.*, "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line," *Proceedings of the National Academy of Science USA*, 89: 4495-4499, 1992.
	C69	Tlsty, Thea D., "Normal diploid human and rodent cells lack a detectable frequency of gene amplification," *Proceedings of the National Academy of Science USA*, 87: 3132-3136, 1990.
	C70	Van Meir *et al.*, "Release of an Inhibitor of Angiogenesis Upon Induction of Wild Type p53 Expression in Glioblastoma Cells," *Nature Genetics*, 8:171-176, October 1994.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant's	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C71	Vincent *et al.*, "Gene Therapy for Malignant Brain Tumors," *Cancer Gene Therapy*, 1(4):328, Abstract No. V-80, San Diego, California, November 10-12, 1994.
	C72	Vogelstein *et al.*, "Genetic Alterations Accumulate During Colorectal Tumorigenesis," Negative Controls on Cell Growth, *Journal of Cellular Biochemistry*, USLA Symposia on Molecular and Cellular Biology, 19th Annual Meetings, February 3-March 11, 1990, Abstract #I004, Supplement 14C, 1990.
	C73	Wahl *et al.*, "Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis," *Nature Medicine*, 2(1): 72-79, 1996.
	C74	Wu and Levine, "p53 and E2F-1 Cooperate to Mediate Apoptosis," *Proc Natl Acad Sci USA*, 91:3602-3606, April 1994.
	C75	Yonish-Rouach *et al.*, "Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6," *Nature*, 352: 345-347, 1991.
	C76	Mi *et al.*, "Base Excision Repair of 5-Hydroxymethyl-2'-Deoxyuridine (HMDURD) from DNA Induces High Molecular Weight DNA Double Strand Breaks and Apoptosis in Mammalian Fibroblasts Containing Mutant "P53," *Proceed. Amer. Assoc. Cancer Res.*, abstract 169, 37:24, March 1996.
	C77	Venkatachalam *et al.*, "Modulation of DNA Damage Induced P53 Response in Human Cells, *Proceed. of the Amer. Assoc. Cancer Res.*, abstract 951, 37:137, 1996.
	C78	Stierum *et al.*, "Inhibition of Poly(ADP-Ribose) Polymerase Increases (+-)-Anti-Benzo (A) Pyrene Diolepoxide-Induced Micronuclei Formation and P53 Accumulation in Isolated Human Peripheral Blood Lymphocytes," *Carcinogenesis*, 16(11):2765-2771, 1996.
	C79	Fanjul *et al.*, "A New Class of Retinoids With Selective Inhibition of AP-1 Inhibits Proliferation", *Nature*, 372(6501):107-111, 1994.
	C80	*In: Dictionary of Natural Compounds, Volume One*," Chapman and Hall, London, 1151, Entry C-01948, 1994.
	C81	*In: Dictionary of Natural Compounds, Volume One*," Chapman and Hall, London, 1151, Entry N-00835, 1994.
	C82	Lane, "P53, Guardian of the Genome," *Nature*, 358:15-16, 1992.

Examiner:	**Date Considered:**

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (modified)	Atty. Docket No. INRP:032--1/HYL	Serial No. 08/675,887
List of Patents and Publications for Applicant's	Applicant	
INFORMATION DISCLOSURE STATEMENT	Ruth A. Gjerset	
(Use several sheets if necessary)	Filing Date: July 5, 1996	Group: 1642

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C83	Rauchuang Ding *et al.*, "Depletion of Poly(ADP-Ribose) Polymerase by Antisense RNA Expression Results in a Delay in DNA Strand Break Rejoining," *J. Biol. Chem.*, 267(18):12804-12812, 1992.
	C84	International Search Report, November 14, 1997 (INGN:032P--)
	C85	Del Bino *et al.*, "Apoptotic cell death triggered by camptothecin or teniposide. The cell cycel specificity and effects of ionizing radiation," *Cell Prolif.*, 25:537-548, 1992.
	C86	Dermer, "Another anniversary for the war on cancer," *Bio/Technology*, 12:320, 1994.
	C87	Gotz *et al.*, "p53: DNA damage, DNA repair, and apoptosis," *Rev. Physiol. Biochem. Pharmacol.*, 127:65-85, 1995.
	C88	Gura, "Systems for identifying new drugs are often faulty," *Science*, 278:1041-1042, 1997.
	C89	Li *et al.*, "Induction of apoptosis by b-lapachone in human prostate cancer cells," *Cancer Res.*, 55(17):3712-3715, 1995.
	C90	Wang *et al.*, "The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway," *Genes Dev.*, 10:1219-1232, 1996.

Examin r:	Date Considered:

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.